News

pharmaphorum4d
Lilly hit as PBM drops Zepbound, but retains Wegovy
Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...
WHO set to back use of weight-loss drugs Wegovy, Zepbound for adults globally
This marks a shift in the agency's approach to treating the global obesity problem. Read more at straitstimes.com. Read more ...
CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans
CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...
Wegovy treated a serious form of liver disease in a major clinical trial
Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...
Weight-loss injections surge as 15M Americans turn to Ozempic, Wegovy for quick results
As summer approaches, millions of Americans are turning to weight-loss injections in hopes of shedding pounds—fast. Roughly ...
Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge
Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...
Lilly’s Q1 2025 revenue jumps 45%, but CVS shift boosts Novo’s Wegovy
Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.
Scientific American6d
Why Ozempic and Wegovy Might Change Some People’s Favorite Foods
Some users of GLP-1 weight-loss drugs have been reporting strange changes in food preferences, such as a new dislike for ...